The Recall Desk
HighFDA (Devices)·Z-2877-2026·Announced 2026-08-12

FilmArray NGDS Warrior Panel Diagnostic Test Recalled Due to Strain Mismatch

Biofire Defense is recalling FilmArray NGDS Warrior Panel kits because the test may not correctly identify certain outbreak strains due to mismatches with the reference strain used during development.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: The recall involves a diagnostic test for high-risk pathogens (e.g., Ebola, Anthrax) where a mismatch poses a risk of harm through potential false negatives, though no illnesses have been reported.

Plain-English summary

Biofire Defense is recalling the FilmArray NGDS Warrior Panel (REF NGDS-ASY-0007), a qualitative, multiplexed, nucleic acid-based in vitro diagnostic test used with the FilmArray 2.0 system. The test is designed to detect and identify Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, and Marburg virus nucleic acids from human whole blood.

The manufacturer identified mismatches between the outbreak strains and the reference strain used during the development of this diagnostic panel. This mismatch may affect the test's ability to accurately detect the target pathogens.

This recall affects 122 kits (3,660 pouches) distributed nationwide across several U.S. states, including AL, CA, DC, FL, GA, HI, KY, LA, MA, MD, MN, NC, NH, NV, NY, OH, RI, TN, TX, UT, VA, and WA. Affected lots include 311825D, 312025D, 313526D, and 322925D.

The recalled product

Product
FilmArray NGDS Warrior Panel REF NGDS-ASY-0007 UDI-DI code: (01)00851458005136 The FilmArray NGDS Warrior Panel is a qualitative, multiplexed, nucleic acid-based in vitro diagnostic test intended for use with the FilmArray 2.0 system. The FilmArray NGDS Warrior Panel detects
Manufacturer
Biofire Defense

Distribution

Distributed nationwide across the United States.

The notice also names 22 states specifically: